A Venue-Based Approach to Asymptomatic Mpox Screening and Doxy-PEP Provision: From Outbreak to Outreach, San Francisco, California, 2023‒2024.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 41411638.
- Also identified by DOI 10.2105/AJPH.2025.308309 and PMC identifier 12895882.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The 2022 global outbreak of clade IIb mpox disproportionately impacted lesbian, gay, bisexual, transgender, and queer (LGBTQ+) communities and highlighted issues of stigma, access to health care, and health care‒associated trauma. Together with LGBTQ+ community partners, our research team implemented venue-based mpox virus and antibody testing. In response to feedback from our community partners, this effort evolved to include broader elements of sexual health services, including distribution of prescriptions for doxycycline postexposure prophylaxis. (<i>Am J Public Health</i>. 2026;116(3):307-311. https://doi.org/10.2105/AJPH.2025.308309).
Medical subject headings
- Disease Outbreaks
- Doxycycline
- Mass Screening
- Post-Exposure Prophylaxis
- Pre-Exposure Prophylaxis
- Sexual and Gender Minorities
- Mpox, Monkeypox